Dublin, Sept. 13, 2021 (GLOBE NEWSWIRE) -- The "ADME-Toxicology Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
Global ADME-Toxicology Testing Market to Reach $10.2 Billion by 2027
Amid the COVID-19 crisis, the global market for ADME-Toxicology Testing estimated at US$5.2 Billion in the year 2020, is projected to reach a revised size of US$10.2 Billion by 2027, growing at a CAGR of 10.1% over the analysis period 2020-2027.
Cell Culture, one of the segments analyzed in the report, is projected to record a 11.7% CAGR and reach US$4.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the High Throughput segment is readjusted to a revised 8.1% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 13.3% CAGR
The ADME-Toxicology Testing market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2027 trailing a CAGR of 13.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.9% and 8.6% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.8% CAGR.
Molecular Imaging Segment to Record 9.8% CAGR
In the global Molecular Imaging segment, USA, Canada, Japan, China and Europe will drive the 9.1% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$860.6 Million in the year 2020 will reach a projected size of US$1.6 Billion by the close of the analysis period.
China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027, while Latin America will expand at a 11.2% CAGR through the analysis period.
Key Topics Covered:
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
- ADME-Tox Testing Gains Traction
- Recent Market Activity
- A Peek into the Impact of ADME-Tox Screening on New Drug Discovery
- Current and Future Analysis
- US and Europe Dominate, Asia-Pacific Lends Growth Momentum
- Growth Momentum Shifts Away from In Vivo Technologies; In Vitro Technologies to Lead the Charge
- Pharma Industry Renews Focus on Cost Optimization
- China and India: Hot Spots for R&D Investment
- ADME-Tox Assays - An Overview
- Introduction of Early In Vitro ADMET Studies
- Growing Prominence of Cell-based Assays in Drug Discovery and ADME Analysis
- Major Types of Cell-Based HTS Assays for Drug Screening
- CROs Expand Presence
- Drug Discovery Outsourcing and Type of Services Outsourced
- Changing Face of Drug Discovery Outsourcing Activity
- M&A - Order of the Day
- Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS (Total 69 Featured)
- ACEA Biosciences, Inc. (USA)
- ADMEcell, Inc. (USA)
- Agilent Technologies, Inc. (USA)
- Albany Molecular Research, Inc. (USA)
- Beckman Coulter, Inc. (USA)
- BioreclamationIVT, LLC (USA)
- Cerep SA (France)
- CompuDrug International, Inc. (USA)
- Cyprotex PLC. (UK)
- CeeTox, Inc. (USA)
- Dassault Systemes Biovia Corp. (USA)
- Eurofins ADME BIOANALYSES SAS (France)
- Galapagos NV (Belgium)
- Molecular Discovery Ltd. (UK)
- MultiCASE, Inc. (USA)
- Optivia Biotechnology (USA)
- PerkinElmer, Inc. (USA)
- Pharmaron, Inc. (USA)
- Promega Corporation (USA)
- Qualyst, Inc. (USA)
- Simulations Plus, Inc. (USA)
- Taconic Biosciences, Inc. (USA)
- Takara Bio Europe AB (Sweden)
- Tecan Group Ltd. (Switzerland)
- Thermo Fisher Scientific, Inc. (USA)
3. MARKET TRENDS & DRIVERS
- Current State of ADME-Tox Testing
- Need for Better Models: A Major Factor Driving Innovation in the Market
- Focus Shifts to Innovative Approaches
- In Silico and In Vitro- the Way to Go
- In Vitro Testing Systems and Its Relevance in Drug Development
- Growing Inclination towards In-vitro Assays for Toxicology Studies
- In Silico ADME-Tox Growing at a Fast Clip
- Advantages of Using In Silico Approaches
- Factors Hindering Growth
- 3-D Tissue Bioassays to Enhance In Vitro Toxicity Testing
- Increasing Use of Cell-Based Assays over Other Methods in Toxicity Testing
- Rising Number of Drug Targets Surge Demand for Cell-Based Assays
- Growing Focus on the Development of Reproducible and Robust Cell-based Assays
- Functional Assays: An Effective Way of Predicting Specific Toxic Effects
- GPCR Targets to Drive Growth in Functional Cell Assay Market
- New Alternatives for Early-Stage Toxicology Testing
- Stem Cells Exude Great Potential in Drug Toxicity Testing
- Primary Hepatocytes Become Standard Tool for Evaluation in Hepatic Metabolism
- Improved Cryopreservation Technologies Help Expand Use of Hepatocytes
- Cardiotoxicity Testing Gains Prominence
- Cell Imaging-Gaining Popularity
- In Vivo Imaging Persists in ADME-Tox Testing
- Computational Models on Rise
- Adoption of Data Management Systems
- Drug Transporter Analysis Becoming Part of ADME Assessment
- Slow Metabolism of Novel Drugs Call for More Human Models in Screening
- Further Advances Required for More Understanding of Biotransformation
- Introduction of Third Dimension in Cell Culturing Drives Need for New Instrumentation
- Regulatory Bodies Focus on Transporter Mediated DDIs
4. GLOBAL MARKET PERSPECTIVE
III. MARKET ANALYSIS
IV. COMPETITION
For more information about this report visit https://www.researchandmarkets.com/r/ukxl9a
